Compare Comcast Corporation (CMCSA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Incyte Corporation — how do they compare? Comcast Corporation trades at $25.19 (market cap $91.02B), while Incyte Corporation trades at $121.08 (market cap $24.54B). The key difference: Comcast Corporation is far larger — about 3.7× Incyte Corporation's market cap, and Comcast Corporation pays a 5.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CMCSA | INCY | |
|---|---|---|
Market Cap | $91.02B | $24.54B |
Sector | Media | Health |
52-Week High | $32.50 | $129.93 |
52-Week Low | $21.92 | $81.61 |
Enterprise Value | $173.74B | $20.04B |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CMCSA trades at $25.185, down slightly by 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The company shows strong fundamentals with a low P/E of 8.22, consistent earnings beats in recent quarters, and robust cash flow generation of $33.64 billion from operations in 2025. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff.
The outlook for CMCSA is positive, supported by attractive valuation, steady dividend payments, and growth in wireless and streaming. Key risks include competitive pressures in media and broadband, execution of the spinoff, and macroeconomic sensitivity. Analyst consensus is bullish with a $27.78 price target, implying potential upside from current levels.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
